Literature DB >> 6326790

The influence of urinary pH on flecainide excretion and its serum pharmacokinetics.

K A Muhiddin, A Johnston, P Turner.   

Abstract

The effect of urinary pH on flecainide excretion has been evaluated in six healthy subjects after a single oral dose of 300 mg flecainide administered as the acetate salt. The cumulative urinary excretion of unchanged flecainide under acidic conditions (134.0 +/- 16.1 mg; mean +/- s.e. mean) was significantly higher than under alkaline conditions (22.3 +/- 7.6 mg; mean +/- s.e. mean) (P less than 0.01). Under alkaline conditions, tmax (time to reach peak concentration) was reduced (P less than 0.01), while elimination half-life, AUC(0-32) and AUC(0-infinity) were increased (P less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6326790      PMCID: PMC1463395          DOI: 10.1111/j.1365-2125.1984.tb02370.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Antiarrhythmics. 2. Synthesis and antiarrhythmic activity of N-(piperidylalkyl)trifluoroethoxybenzamides.

Authors:  E H Banitt; W R Bronn; W E Coyne; J R Schmid
Journal:  J Med Chem       Date:  1977-06       Impact factor: 7.446

2.  Buccal absorption of basic drugs and its application as an in vivo model of passive drug transfer through lipid membranes.

Authors:  A H Beckett; E J Triggs
Journal:  J Pharm Pharmacol       Date:  1967-12       Impact factor: 3.765

3.  A study of the influence of pH on the buccal absorption and renal excretion of procainamide.

Authors:  W Meyer; C M Kaye; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1974-07-26       Impact factor: 2.953

4.  STRIPE: an interactive computer program for the analysis of drug pharmacokinetics.

Authors:  A Johnston; R C Woollard
Journal:  J Pharmacol Methods       Date:  1983-05

5.  The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers.

Authors:  A Johnston; C D Burgess; S J Warrington; J Wadsworth; N A Hamer
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

6.  Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide.

Authors:  H J Duff; D M Roden; R J Maffucci; B S Vesper; G J Conard; S B Higgins; J A Oates; R F Smith; R L Woosley
Journal:  Am J Cardiol       Date:  1981-12       Impact factor: 2.778

7.  Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent.

Authors:  M Hodges; J M Haugland; G Granrud; G J Conard; R W Asinger; F L Mikell; J Krejci
Journal:  Circulation       Date:  1982-05       Impact factor: 29.690

8.  Suppression of complex ventricular arrhythmias by oral flecainide.

Authors:  D Duran; E V Platia; L S Griffith; G Adhar; P R Reid
Journal:  Clin Pharmacol Ther       Date:  1982-11       Impact factor: 6.875

  8 in total
  18 in total

1.  Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia.

Authors:  Kosuke Doki; Masato Homma; Keisuke Kuga; Kazutomi Kusano; Shigeyuki Watanabe; Iwao Yamaguchi; Yukinao Kohda
Journal:  Eur J Clin Pharmacol       Date:  2006-08-30       Impact factor: 2.953

2.  Elimination of flecainide as a function of urinary flow rate and pH.

Authors:  R Hertrampf; U Gundert-Remy; J Beckmann; U Hoppe; W Elsässer; H Stein
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

4.  Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.

Authors:  A S Gross; G Mikus; C Fischer; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Safety of flecainide.

Authors:  Juan Tamargo; Alessandro Capucci; Philippe Mabo
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

6.  Altered flecainide disposition in healthy volunteers taking quinine.

Authors:  A Munafo; G Reymond-Michel; J Biollaz
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.

Authors:  A S Gross; G Mikus; C Fischer; R Hertrampf; U Gundert-Remy; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

9.  Flecainide: evidence of non-linear kinetics.

Authors:  G Boriani; E Strocchi; A Capucci; R Callivà; L Frabetti; E Ambrosioni; B Magnani
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Primary and secondary detoxification in severe flecainide intoxication.

Authors:  D Götz; S Pohle; D Barckow
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.